Plain-English translation of NCT07583511 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether works as well as or better than when combined with and for treating extensive-stage small-cell lung cancer. Both chemotherapy combinations include the same two other drugs, but the study is comparing which version of the first drug works best. The goal is to find the most effective treatment option for people with this advanced form of lung cancer.
Small-cell lung cancer is aggressive and spreads quickly, making it challenging to treat. Researchers want to see if using instead of the standard might help patients live longer and stay cancer-free longer with this medication combination.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive one of two chemotherapy combinations, each given by injection and/or capsule. The study tracks how long you survive without your cancer getting worse (called progression-free survival). You would have regular clinic visits for treatment administration, blood tests, and scans to monitor how well the medication is working and to watch for side effects.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Sun Yat-sen University
Enrollment target
~90 participants
Started
February 2024
Primary completion
May 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wenfeng Fang
Sun Yat-Sen University Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.